Haller MJ, et al. - The Type 1 Diabetes TrialNet Study Group conducted a three-arm, randomized, double-masked, placebo-controlled phase 2b trial that previously showed low-dose anti-thymocyte globulin (ATG, 2.5mg/kg) preserved β-cell function and lowered HbA1c in new-onset type 1 diabetes for one year, so researchers reported AUC C-peptide and HbA1c pre-specified secondary endpoints and potential immunologic correlates after 2 years. In those treated with ATG and ATG/granulocyte-colony stimulating factor (GCSF) vs placebo, HbA1c was significantly reduced at 2 years. In new-onset type 1 diabetes two years after therapy, low-dose ATG maintained β-cell function in part and lowered HbA1c.